Skip to main content
. 2023 Jul 1;31(9):2651–2661. doi: 10.1016/j.ymthe.2023.06.018

Figure 5.

Figure 5

Genetic or pharmacological activation of TRPML1 ameliorates liver disease of PiZ mice

Graphic representation of therapeutic efficacy of TRPML1-mediated lysosomal exocytosis in PiZ mice. Delivery of ATZ polymers to lysosome for exocytosis may rely on ER-to-lysosome-associated degradation pathway (ERLAD) (1) or autophagosome-lysosome fusion (2).